BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 26645158)

  • 1. Targeting of Carbon Ion-Induced G2 Checkpoint Activation in Lung Cancer Cells Using Wee-1 Inhibitor MK-1775.
    Ma H; Takahashi A; Sejimo Y; Adachi A; Kubo N; Isono M; Yoshida Y; Kanai T; Ohno T; Nakano T
    Radiat Res; 2015 Dec; 184(6):660-9. PubMed ID: 26645158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting radiation-induced G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines.
    Sarcar B; Kahali S; Prabhu AH; Shumway SD; Xu Y; Demuth T; Chinnaiyan P
    Mol Cancer Ther; 2011 Dec; 10(12):2405-14. PubMed ID: 21992793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.
    Bridges KA; Hirai H; Buser CA; Brooks C; Liu H; Buchholz TA; Molkentine JM; Mason KA; Meyn RE
    Clin Cancer Res; 2011 Sep; 17(17):5638-48. PubMed ID: 21799033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence.
    Osman AA; Monroe MM; Ortega Alves MV; Patel AA; Katsonis P; Fitzgerald AL; Neskey DM; Frederick MJ; Woo SH; Caulin C; Hsu TK; McDonald TO; Kimmel M; Meyn RE; Lichtarge O; Myers JN
    Mol Cancer Ther; 2015 Feb; 14(2):608-19. PubMed ID: 25504633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiosensitization of NSCLC cells to X-rays and carbon ions by the CHK1/CHK2 inhibitor AZD7762, Honokiol and Tunicamycin.
    Liu B; Chen W; Li H; Li F; Jin X; Li Q
    Radiat Environ Biophys; 2020 Nov; 59(4):723-732. PubMed ID: 32857208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents.
    Leijen S; Beijnen JH; Schellens JH
    Curr Clin Pharmacol; 2010 Aug; 5(3):186-91. PubMed ID: 20406171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy.
    Yang L; Shen C; Pettit CJ; Li T; Hu AJ; Miller ED; Zhang J; Lin SH; Williams TM
    Clin Cancer Res; 2020 Jul; 26(14):3740-3750. PubMed ID: 32220892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. G2-checkpoint targeting and radiosensitization of HPV/p16-positive HNSCC cells through the inhibition of Chk1 and Wee1.
    Busch CJ; Kröger MS; Jensen J; Kriegs M; Gatzemeier F; Petersen C; Münscher A; Rothkamm K; Rieckmann T
    Radiother Oncol; 2017 Feb; 122(2):260-266. PubMed ID: 27939202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokinetic effects of Wee1 disruption in pancreatic cancer.
    Chang Q; Chandrashekhar M; Ketela T; Fedyshyn Y; Moffat J; Hedley D
    Cell Cycle; 2016; 15(4):593-604. PubMed ID: 26890070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiosensitization of metformin in pancreatic cancer cells via abrogating the G2 checkpoint and inhibiting DNA damage repair.
    Wang Z; Lai ST; Ma NY; Deng Y; Liu Y; Wei DP; Zhao JD; Jiang GL
    Cancer Lett; 2015 Dec; 369(1):192-201. PubMed ID: 26304716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abrogating G₂/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma.
    Indovina P; Marcelli E; Di Marzo D; Casini N; Forte IM; Giorgi F; Alfano L; Pentimalli F; Giordano A
    Cancer Biol Ther; 2014 Apr; 15(4):380-8. PubMed ID: 24365782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Not so WEE: targeting G₂/M to kill mesothelioma cells.
    Dent P
    Cancer Biol Ther; 2014 Apr; 15(4):351-2. PubMed ID: 24496096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia.
    Caldwell JT; Edwards H; Buck SA; Ge Y; Taub JW
    Pediatr Blood Cancer; 2014 Oct; 61(10):1767-73. PubMed ID: 24962331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nontoxic concentration of DNA-PK inhibitor NU7441 radio-sensitizes lung tumor cells with little effect on double strand break repair.
    Sunada S; Kanai H; Lee Y; Yasuda T; Hirakawa H; Liu C; Fujimori A; Uesaka M; Okayasu R
    Cancer Sci; 2016 Sep; 107(9):1250-5. PubMed ID: 27341700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication Stress.
    Cuneo KC; Morgan MA; Davis MA; Parcels LA; Parcels J; Karnak D; Ryan C; Liu N; Maybaum J; Lawrence TS
    Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):782-90. PubMed ID: 26975930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining carbon ion irradiation and non-homologous end-joining repair inhibitor NU7026 efficiently kills cancer cells.
    Ma H; Takahashi A; Yoshida Y; Adachi A; Kanai T; Ohno T; Nakano T
    Radiat Oncol; 2015 Nov; 10():225. PubMed ID: 26553138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiosensitizing effect of carboplatin and paclitaxel to carbon-ion beam irradiation in the non-small-cell lung cancer cell line H460.
    Kubo N; Noda SE; Takahashi A; Yoshida Y; Oike T; Murata K; Musha A; Suzuki Y; Ohno T; Takahashi T; Nakano T
    J Radiat Res; 2015 Mar; 56(2):229-38. PubMed ID: 25599995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer.
    Geenen JJJ; Schellens JHM
    Clin Cancer Res; 2017 Aug; 23(16):4540-4544. PubMed ID: 28442503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.
    Richer AL; Cala JM; O'Brien K; Carson VM; Inge LJ; Whitsett TG
    Cancer Res; 2017 Sep; 77(17):4663-4672. PubMed ID: 28652249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WEE1 kinase inhibitor MK-1775 sensitizes oral tongue squamous cell carcinoma cells to radiation irrespective of TP53 status.
    Al-Jamaei AH; de Visscher JGAM; Subramanyam VR; Forouzanfar T; Sminia P; Doulabi BZ; Helder MN
    Oral Dis; 2023 Oct; 29(7):2640-2649. PubMed ID: 35672254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.